This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Govindan, R. Articles by Piccirillo, J. Search for Related Content PubMed PubMed Citation Articles by Govindan, R. Articles by Piccirillo, J. Related Articles Related Editorial Social Bookmarking                            What's this?

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William Read, Ryan Tierney, Anna Vlahiotis, Edward L. Spitznagel, Jay Piccirillo

From the Departments of Internal Medicine, Otolaryngology-Head and Neck Surgery, Psychiatry, and Mathematics, Washington University School of Medicine, St Louis, MO; and the University of California-San Diego, San Diego, CA

Address reprint requests to Ramaswamy Govindan, MD, Division of Oncology, Washington University School of Medicine, 4960 Children's Place, Suite 108, St Louis, MO 63110; e-mail: rgovinda{at}im.wustl.edu

PURPOSE: Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years.

METHODS: We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance.

RESULTS: The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period.

CONCLUSION: Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Changing Face of Small-Cell Lung Cancer: Real and Artifact
  David S. Ettinger and Joseph Aisner
  JCO 2006 24: 4526-4527 [Full Text]

This article has been cited by other articles:

				T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer Ann. Onc., October 8, 2009; (2009) mdp401v1. [Abstract] [Full Text] [PDF]

				M. A. Socinski, E. F. Smit, P. Lorigan, K. Konduri, M. Reck, A. Szczesna, J. Blakely, P. Serwatowski, N. A. Karaseva, T. Ciuleanu, et al. Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer J. Clin. Oncol., October 1, 2009; 27(28): 4787 - 4792. [Abstract] [Full Text] [PDF]

				M. J. Titulaer, R. Klooster, M. Potman, L. Sabater, F. Graus, I. M. Hegeman, P. E. Thijssen, P. W. Wirtz, A. Twijnstra, P. A.E. S. Smitt, et al. SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival J. Clin. Oncol., September 10, 2009; 27(26): 4260 - 4267. [Abstract] [Full Text] [PDF]

				P. Wheatley-Price, C. Ma, L. F. Ashcroft, M. Nankivell, R. J. Stephens, S. C. White, P. Lorigan, N. Thatcher, F. H. Blackhall, and F. A. Shepherd The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit Ann. Onc., August 12, 2009; (2009) mdp300v1. [Abstract] [Full Text] [PDF]

				S. M. Lee, P. J. Woll, R. Rudd, D. Ferry, M. O'Brien, G. Middleton, S. Spiro, L. James, K. Ali, M. Jitlal, et al. Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial J Natl Cancer Inst, August 5, 2009; 101(15): 1049 - 1057. [Abstract] [Full Text] [PDF]

				M. C. Crisanti, A. F. Wallace, V. Kapoor, F. Vandermeers, M. L. Dowling, L. P. Pereira, K. Coleman, B. G. Campling, Z. G. Fridlender, G. D. Kao, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2221 - 2231. [Abstract] [Full Text] [PDF]

				H. Bai, L. Mao, h. S. Wang, J. Zhao, L. Yang, t. T. An, X. Wang, c. J. Duan, n. M. Wu, z. Q. Guo, et al. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2009; 27(16): 2653 - 2659. [Abstract] [Full Text] [PDF]

				Y.-T. Huang, R. S. Heist, L. R. Chirieac, X. Lin, V. Skaug, S. Zienolddiny, A. Haugen, M. C. Wu, Z. Wang, L. Su, et al. Genome-Wide Analysis of Survival in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2009; 27(16): 2660 - 2667. [Abstract] [Full Text] [PDF]

				P. N. Lara Jr, R. Natale, J. Crowley, H. J. Lenz, M. W. Redman, J. E. Carleton, J. Jett, C. J. Langer, J. P. Kuebler, S. R. Dakhil, et al. Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124 J. Clin. Oncol., May 20, 2009; 27(15): 2530 - 2535. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Current Treatments for Advanced Stage Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241. [Abstract] [Full Text] [PDF]

				K. Bogos, F. Renyi-Vamos, J. Dobos, I. Kenessey, J. Tovari, J. Timar, J. Strausz, G. Ostoros, W. Klepetko, H. J. Ankersmit, et al. High VEGFR-3-positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer Clin. Cancer Res., March 1, 2009; 15(5): 1741 - 1746. [Abstract] [Full Text] [PDF]

				T. Budak-Alpdogan, B. Chen, A. Warrier, D. J. Medina, D. Moore, and J. R. Bertino Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma Clin. Cancer Res., February 15, 2009; 15(4): 1232 - 1240. [Abstract] [Full Text] [PDF]

				T. Jiang, B. J. Collins, N. Jin, D. N. Watkins, M. V. Brock, W. Matsui, B. D. Nelkin, and D. W. Ball Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer Cancer Res., February 1, 2009; 69(3): 845 - 854. [Abstract] [Full Text] [PDF]

				P. Ceppi, S. Novello, A. Cambieri, M. Longo, V. Monica, M. Lo Iacono, M. Giaj-Levra, S. Saviozzi, M. Volante, M. Papotti, et al. Polymerase {eta} mRNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy Clin. Cancer Res., February 1, 2009; 15(3): 1039 - 1045. [Abstract] [Full Text] [PDF]

				B. J. Slotman, M. E. Mauer, A. Bottomley, C. Faivre-Finn, G. W.P.M. Kramer, E. M. Rankin, M. Snee, M. Hatton, P. E. Postmus, L. Collette, et al. Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms--Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups J. Clin. Oncol., January 1, 2009; 27(1): 78 - 84. [Abstract] [Full Text] [PDF]

				C. L. Hann and D. S. Ettinger The Change in Pattern and Pathology of Small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 451 - 454. [Abstract] [Full Text] [PDF]

				L. M. Krug and M. C. Pietanza Emerging Therapies in Small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 455 - 460. [Abstract] [Full Text] [PDF]

				A. Inoue, S. Sugawara, K. Yamazaki, M. Maemondo, T. Suzuki, K. Gomi, S. Takanashi, C. Inoue, M. Inage, H. Yokouchi, et al. Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 J. Clin. Oncol., November 20, 2008; 26(33): 5401 - 5406. [Abstract] [Full Text] [PDF]

				J. P. Sculier, J. J. Lafitte, A. Efremidis, M. C. Florin, J. Lecomte, M. C. Berchier, M. Richez, T. Berghmans, A. Scherpereel, A. P. Meert, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer Ann. Onc., October 1, 2008; 19(10): 1691 - 1697. [Abstract] [Full Text] [PDF]

				M. J. Titulaer, P. W. Wirtz, L. N.A. Willems, K. W. van Kralingen, P. A.E. S. Smitt, and J. J.G.M. Verschuuren Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome J. Clin. Oncol., September 10, 2008; 26(26): 4276 - 4281. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? Oncologist, September 1, 2008; 13(9): 933 - 944. [Abstract] [Full Text] [PDF]

				C. D. Peacock and D. N. Watkins Cancer Stem Cells and the Ontogeny of Lung Cancer J. Clin. Oncol., June 10, 2008; 26(17): 2883 - 2889. [Abstract] [Full Text] [PDF]

				G. J. Weiss, L. T. Bemis, E. Nakajima, M. Sugita, D. K. Birks, W. A. Robinson, M. Varella-Garcia, P. A. Bunn Jr, J. Haney, B. A. Helfrich, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Ann. Onc., June 1, 2008; 19(6): 1053 - 1059. [Abstract] [Full Text] [PDF]

				S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]

				T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]

				C. P. Belani, S. Ramalingam, M. C. Perry, R. V. LaRocca, D. Rinaldi, P. S. Gable, and W. J. Tester Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., January 20, 2008; 26(3): 468 - 473. [Abstract] [Full Text] [PDF]

				S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599 J. Clin. Oncol., January 1, 2008; 26(1): 60 - 65. [Abstract] [Full Text] [PDF]

				A. M. Arnold, L. Seymour, M. Smylie, K. Ding, Y. Ung, B. Findlay, C. W. Lee, M. Djurfeldt, M. Whitehead, P. Ellis, et al. Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 J. Clin. Oncol., September 20, 2007; 25(27): 4278 - 4284. [Abstract] [Full Text] [PDF]

				M. A. Socinski and J. A. Bogart Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145. [Abstract] [Full Text] [PDF]

				B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? Oncologist, September 1, 2007; 12(9): 1096 - 1104. [Abstract] [Full Text] [PDF]

				B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, P. Postmus, L. Collette, E. Musat, S. Senan, et al. Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer N. Engl. J. Med., August 16, 2007; 357(7): 664 - 672. [Abstract] [Full Text] [PDF]

				C. Schairer, M. Hisada, B. E. Chen, L. M. Brown, R. Howard, S. D. Fossa, M. Gail, and L. B. Travis Comparative Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers J Natl Cancer Inst, August 15, 2007; 99(16): 1248 - 1256. [Abstract] [Full Text] [PDF]

				J. R. Eckardt, J. von Pawel, J.-L. Pujol, Z. Papai, E. Quoix, A. Ardizzoni, R. Poulin, A. J. Preston, G. Dane, and G. Ross Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2086 - 2092. [Abstract] [Full Text] [PDF]

				J. A. Garcia and B. I. Rini Recent Progress in the Management of Advanced Renal Cell Carcinoma CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125. [Abstract] [Full Text] [PDF]

				D. S. Ettinger and J. Aisner Changing Face of Small-Cell Lung Cancer: Real and Artifact J. Clin. Oncol., October 1, 2006; 24(28): 4526 - 4527. [Full Text] [PDF]